3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
4
Sarcoma
1
Gynecologic
1
CNS
1
Conditions
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
Magnetic Resonance Spectroscopy
76
Temozolomide
73
Specimen Handling
49
Radiotherapy
46
Radiosurgery
34
Cyclophosphamide
28
Bevacizumab
26
Radiation
25
pembrolizumab
24
Biopsy
23
Nivolumab
21
Carboplatin
16
fludarabine
14
X-Rays
13
Ipilimumab
13
Surgical Procedures, Operative
12
Lomustine
12
Irinotecan
12
Vincristine
11
Topotecan
11
Cisplatin
11
Blood Specimen Collection
11
dinutuximab
10
trametinib
9
abemaciclib
9
AZD 6244
9
lutetium Lu 177 dotatate
8
Immunoglobulin G
8
Etoposide
8
Doxorubicin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
RAD1901
×
CNS
×
90 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled